<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620425</url>
  </required_header>
  <id_info>
    <org_study_id>ZX001-0703</org_study_id>
    <nct_id>NCT00620425</nct_id>
  </id_info>
  <brief_title>A Study on the Effects of Repeat Doses of IntrajectÂ® Sumatriptan on Local Site Signs</brief_title>
  <official_title>A Single-Center, Open-label, Single-Arm Study to Evaluate the Effects of Repeat Doses of Subcutaneously Delivered Sumatriptan Via the Intraject System of Local Injection Site Signs in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled
      with 6 mg sumatriptan. Healthy Individuals will be enrolled for a series of 3 injections over
      2 days. Assessment of Local Site Signs will be recorded for up to 5 days, as needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the extent, persistence, and any cumulative effects on skin tissue
      by assessing local injection site reactions (bleeding, swelling, erythema, bruising)
      following repeated administrations of needle-free Intraject sumatriptan to the same anatomic
      site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema).</measure>
    <time_frame>-15 min, immediately Post-dose, and 1, 4, 8, 24, 48 and 72 hrs post-dose</time_frame>
    <description>Each of the 18 participants were injected three times (for a total of 54 injections)with Sumavel DosePro, and followed over three days.</description>
  </primary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>injection</description>
    <other_name>SUMAVEL(R) DosePro(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of child-bearing potential must agree to use acceptable birth control

          -  Have abdominal or thigh injection sites that have sufficient subcutaneous tissue for
             needle-free injection

          -  Fluent in the spoken and written English language

          -  Provide written informed consent to participate in the study and be willing to comply
             with the study procedures

          -  Non-tobacco user for at least 12 months prior to screening (all types of tobacco,
             including cigars)

        Exclusion Criteria:

          -  A history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral
             vascular syndromes including ischemic or vasospastic coronary artery disease

          -  Other significant underlying cardiovascular diseases including uncontrolled
             hypertension

          -  Hemiplegic or basilar migraine

          -  A history or diagnosis of severe hepatic or renal impairment

          -  A history of epilepsy or seizure or other serious neurologic condition

          -  A history of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its
             components or similar drugs

          -  A history of scleroderma (systemic sclerosis) or any skin condition that may adversely
             affect the injection or absorption of subcutaneously administered medications

          -  Tattoos, birthmarks or other significant skin discoloration in the thigh or abdominal
             area that are large enough to restrict injection site selection and/or evaluation

          -  Pregnancy or breast-feeding

          -  Have participated in a clinical trial or receipt of an experimental therapy within 30
             days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Chandler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>November 1, 2010</results_first_submitted>
  <results_first_submitted_qc>July 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2012</results_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sumatriptan</keyword>
  <keyword>Intraject</keyword>
  <keyword>Local Site Reactions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Every participant received SUMAVEL DosePro at time 0, 1 and 25 hrs. Every participant was monitored for the incidence and persistence of bleeding, bruising, swelling and erythema.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Every participant received SUMAVEL DosePro at time 0, 1 and 25 hrs. Every participant was monitored for the incidence and persistence of bleeding, bruising, swelling and erythema.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema).</title>
        <description>Each of the 18 participants were injected three times (for a total of 54 injections)with Sumavel DosePro, and followed over three days.</description>
        <time_frame>-15 min, immediately Post-dose, and 1, 4, 8, 24, 48 and 72 hrs post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants at -15 Min Pre-dose</title>
            <description>Every participant received SUMAVEL DosePro at time 0, 1 and 25 hrs. Every participant was monitored for the incidence and persistence of bleeding, bruising, swelling and erythema.</description>
          </group>
          <group group_id="O2">
            <title>All Participants Immediately Post-dose</title>
            <description>These are the reactions relative to each injection (total of 3 injections in 18 participants).</description>
          </group>
          <group group_id="O3">
            <title>1 hr Post-dose</title>
            <description>These are the reactions relative to each injection (total of 3 injections in 18 participants).</description>
          </group>
          <group group_id="O4">
            <title>4 hr Post-dose</title>
            <description>These are the reactions relative to each injection (total of 3 injections in 18 participants).</description>
          </group>
          <group group_id="O5">
            <title>8 hr Post-dose</title>
            <description>These are the reactions relative to each injection (total of 3 injections in 18 participants).</description>
          </group>
          <group group_id="O6">
            <title>24 hr Post-dose</title>
            <description>These are the reactions relative to each injection (total of 3 injections in 18 participants).</description>
          </group>
          <group group_id="O7">
            <title>48 hr Post-dose</title>
            <description>These are the reactions relative to each injection (total of 3 injections in 18 participants).</description>
          </group>
          <group group_id="O8">
            <title>72 hr Post-dose</title>
            <description>Only 3 subjects were required to return on Day 4. Day 4 assessments included a 72 hour assessment for the first and second injections and a 48 hour assessment for the third injection.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema).</title>
          <description>Each of the 18 participants were injected three times (for a total of 54 injections)with Sumavel DosePro, and followed over three days.</description>
          <units>injections</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Injections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injections with Bleeding present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injections with Bruising present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injections with Swelling present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injections with Erythema present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Every participant received SUMAVEL DosePro at time 0, 1 and 25 hrs. Every participant was monitored for the incidence and persistence of bleeding, bruising, swelling and erythema.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Smith III, PhD, VP Regulatory Affairs &amp; Product Quality/Safety</name_or_title>
      <organization>Zogenix, Inc</organization>
      <phone>510 550 8325</phone>
      <email>esmith@zogenix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

